SYLLABUS SWI/SNF-dependent tumors
|
|
- Cordelia Watson
- 6 years ago
- Views:
Transcription
1
2 SYLLABUS SWI/SNF-dependent tumors F Le Loarer, MD, PhD Centre Leon Berard, Department of Pathology, Lyon, FRANCE Since the seminal description in 1999 of recurrent inactivation of SMARCB1- which encodes a subunit of SWI/SNF complexes- in malignant rhabdoid tumors, experimental evidence has consistently demonstrated that most subunits of the SWI/SNF complexes act as tumor suppressor genes. We review herein the functions of these complexes and discuss the main types of sarcomas which have been linked to their alteration. SWI/SNF (BAF) complexes basics SWI/SNF (Switch/Sucrose Non Fermentable) complexes were initially purified from yeast. Their human orthologs are called hswi/snf or hbaf (standing for human brahma associated factors) complexes. They are assembled in evolutionarily conserved multiprotein complexes, belonging to the Snf2 family of ATP-dependent helicases. They are made of 8 to 14 subunits which specific assortment provides functional diversity 1. They regulate gene expression through the modification of nucleosomes composition or position across the genome. The complexes are anchored to the nucleosome and DNA, regulating the access of transcription factors to the regulatory regions of target genes 2. BAF complexes and cancer The complexes are frequently targeted in cancer through inactivating mutations of the genes encoding its subunits with an estimated overall frequency of 19,6% in human cancer 3.This broad mutation pattern is similar to that of TP53, suggestive of the major tumor suppressor role played by the complexes. However, these mutations are recurrent in only a few tumor types, a finding suggestive of the driving role that inactivation of BAF complexes play in these subsets of tumors. This review will focus on these entities with a special emphasis on sarcomas. Malignant rhabdoid tumor (MRT) MRT were the first malignancies to be linked to BAF complexes dysfunction. They are underlined by inactivating mutations of SMARCB1 located in 22q11, which gene encodes a key subunit of the BAF complex 4. Clinically, these tumors may locate in central nervous system, referred as atypical rhabdoid/teratoid tumors (AT/RT) or in kidney and soft tissue where they are classically called malignant rhabdoid tumors (MRT). A constitutional mutation is present in 30% of cases 5. This constitutional setting is referred to as rhabdoid predisposition syndrome 1 (OMIM ). Schwannomatosis represents another inherited (OMIM ) related to SMARCB1 mutations predisposing to the development of schwannomas and meningiomas which display loss of SMARCB1 expression in this setting. A genetic variant of AT/RT and MRT has been described in 2011, which is underlined by SMARCA4 inactivation 6. SMARCA4 is located in 19p13.2 and encodes one of the ATPase subunit of the BAF complexes, functionnally related to SMARCB1. Epithelioid sarcoma
3 Epithelioid sarcomas (ES) display a loss of SMARCB1 expression in 90% of cases 7. This immunohistochemical feature is now acknowledged as a mandatory criteria to render the diagnosis of ES. SMARCB1 loss is primarily underlined by genomic deletions in ES 8 while inactivation result from more diverse mechanisms in MRT (mostly inactivating mutation combined with copy neutral-loss of heterozygosity or deletions). Although a unique case of epithelioid sarcoma with constitutional SMARCB1 alteration has been described, this association is probably rare 9. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) Next generation sequencing studies of series of SCCOHT have recently evidenced recurrent SMARCA4 inactivation. This finding combined with the rhabdoid appearance displayed by these tumors and their clinical features (dismal prognosis and frequent association with germline mutation) led to the speculation that SCCOHT represent «malignant ovarian rhabdoid tumors». This hypothesis is supported by transcriptomic studies emphasizing the close vicinity of their transcriptomes with those of SMARCB1 and SMARCA4-inactivated rhabdoid tumors 10. These malignancies are listed along with SMARCA4-mutated MRT in the spectrum of rhabdoid predisposition syndrome 2 (OMIM ). SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) This new tumor subtype consists in mediastino-pulmonary malignancies typically affecting years old male adults (median age : 39 yo). These tumors grow rapidly, displaying an aggressive behaviour with a median survival of 7 months. They consist in sheets of epithelioid to rhabdoid tumor cells expressing at least focally AE1/E3 or EMA, along with diffuse expression of CD34 and SOX2. They are underlined by SMARCA4 mutations and display constant loss of SMARCA4 nuclear expression 10. Preliminary data do not suggest SMARCA4-DTS are associated with constitutional alterations. Although their genomic background is more complex than those of MRT and SCCOHT, their transcriptomes cluster closely together suggesting that common mechanisms are involved in the development of these groups of tumors 10. Epithelioid malignant peripheral nerve sheet tumors (empnst) The epithelioid variant of MPNST display SMARCB1 loss in up to 50% of cases while this feature is not seen in conventional MPNST 7.This loss occurs secondarily to genomic deletions. Myoepithelial carcinoma Myoepithelial carcinoma loose SMARCB1 expression in 10% of cases 7 which loss is underlined by genomic deletions 9. Additionally, a series of SMARCB1-lost neoplasms of vulvar location has been described compiling cases of myoepithelial carcinomas, epithelioid sarcomas as well as tumors with intermediate features 11. However, these cases presumably represent classical cases of these entities rather than a specific entity. The concept of composite rhabdoid tumors It has been hypothesized that rhabdoid microscopic features may represent a surrogate of BAF complex dysfunction. While initial studies conducted with SMARCB1 immunohistochemistry dismissed this hypothesis 12, other investigators reported variants of
4 carcinomas harbouring SMARCB1 loss such as SMARCB1-deficient sinonasal carcinoma 13,14. Furthermore, SMARCB1 and SMARCA4 inactivations have also been described in dedifferentiated variants of carcinomas in the endometrium 15, the GI tract 16, lung 17 and pancreas 18. These findings suggest that BAF complexes alterations may contribute to dedifferentiation in tumors. The term of «composite rhabdoid tumor» prevously proposed to describe tumors which display focal rhabdoid features intermingled with well differentiated areas but is of no practical use. Conversely, tumors may display recurrent loss of expression of BAF complex subunits although they do not display rhabdoid features. Two of them involve original mechanisms. First, synovial sarcomas have long been shown to harbour frequent loss or attenuated expression of varied BAF complexes subunits 19. This peculiar immunophenotype is secondary to the ejection of SMARCB1 subunit from BAF complexes caused by the incorporation of the SS18-SSX fusion protein 20. Renal medullary carcinoma. Second, renal medullary carcinomas (RMC) are aggressive kidney malignancies affecting sickle cell disease patients. RMC display loss of SMARCB1 expression related to a translocation involving SMARCB1, resulting in a truncated non functional protein 21. References 1. Wang, W. et al. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 10, (1996). 2. Saha, A., Wittmeyer, J. & Cairns, B.R. Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 7, (2006). 3. Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45, (2013). 4. Versteege, I. et al. Truncating mutations of hsnf5/ini1 in aggressive paediatric cancer. Nature 394, (1998). 5. Brennan, B., Stiller, C. & Bourdeaut, F. Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncol 14, e (2013). 6. Hasselblatt, M. et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 35, (2011). 7. Hornick, J.L., Dal Cin, P. & Fletcher, C.D. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 33, (2009). 8. Sullivan, L.M., Folpe, A.L., Pawel, B.R., Judkins, A.R. & Biegel, J.A. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol 26, (2013). 9. Le Loarer, F. et al. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer 53, (2014). 10. Le Loarer, F. et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 47, (2015). 11. Folpe, A.L. et al. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases. Am J Surg Pathol 39, (2015). 12. Perry, A., Fuller, C.E., Judkins, A.R., Dehner, L.P. & Biegel, J.A. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol 18, (2005).
5 13. Agaimy, A. et al. SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol 38, (2014). 14. Bishop, J.A., Antonescu, C.R. & Westra, W.H. SMARCB1 (INI-1)-deficient Carcinomas of the Sinonasal Tract. Am J Surg Pathol (2014). 15. Karnezis, A.N. et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol (2016). 16. Agaimy, A., Rau, T.T., Hartmann, A. & Stoehr, R. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 38, (2014). 17. Matsubara, D. et al. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci 104, (2013). 18. Agaimy, A. et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. Mod Pathol 28, (2015). 19. Kohashi, K. et al. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 23, (2010). 20. Kadoch, C. & Crabtree, G.R. Reversible disruption of mswi/snf (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 153, (2013). 21. Calderaro, J. et al. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. Eur Urol (2015).
Case of the month. Dr Charles Bénière, Institut universitaire de pathologie, Lausanne
Case of the month Dr Charles Bénière, Institut universitaire de pathologie, Lausanne Clinical history 39 years old male, smoker (19 pack-year) without any prior medical record nor professional exposure.
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Diagnoses one would not like to miss in soft tissue pathology early in your career Marta Sbaraglia, MD Department of Pathology Hospital of Treviso University of Padua
More informationFinancial disclosures
An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical
More informationA Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Preliminary Activity in INI1-Negative Tumors
A Phase 1 Study of Tazemetostat (EPZ-6438), an Enhancer of Zeste-Homolog 2 (EZH2) Inhibitor: Preliminary Activity in INI1-Negative Tumors A Italiano, H Keilhack, M Toulmonde, J-M Coindre, J-M Michot, C
More informationCase 1. Maysa Al-Hussaini MD FRCPath
Case 1 Maysa Al-Hussaini MD FRCPath MAYSA King AL-HUSSAINI Hussein Cancer MD Center MRCPATH KING HUSSEIN Amman CANCER Jordan CENTER Clinical history 4 year old boy History of frontal headache, sleepiness.
More informationThe first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report
Yoshida et al. BMC Cancer (2018) 18:398 https://doi.org/10.1186/s12885-018-4321-x CASE REPORT Open Access The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationCase Report A SMARCB1-deficient vulvar neoplasm with prominent myxoid stroma: report of a case showing ERG and FLI1 expression
Int J Clin Exp Pathol 2015;8(6):7526-7532 www.ijcep.com /ISSN:1936-2625/IJCEP0008225 Case Report A SMARCB1-deficient vulvar neoplasm with prominent myxoid stroma: report of a case showing ERG and FLI1
More information3/24/2017 DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS. Disclosure of Relevant Financial Relationships
DENDRITIC CELL NEOPLASMS: HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND MOLECULAR GENETICS Jason L. Hornick, M.D., Ph.D. Director of Surgical Pathology and Immunohistochemistry Brigham and Women s Hospital Professor
More informationUpdate on Cutaneous Mesenchymal Tumors. Thomas Brenn
Update on Cutaneous Mesenchymal Tumors Thomas Brenn Cutaneous Mesenchymal Tumours Wide morphological and biological spectrum Myofibroblastic, smooth muscle, neural, vascular, apidocytic, undifferentiated;
More informationUSCAP Pediatrics Evening Subspecialty Conference 2015
USCAP Pediatrics Evening Subspecialty Conference 2015 Sunday 22 March 2015 Alexander Lazar MD/PhD Department of Pathology S Section of Bone Soft TIssue Pathology Sarcoma Research Center The Case Patient
More informationRaymond Auerbach PhD Candidate, Yale University Gerstein and Snyder Labs August 30, 2012
Elucidating Transcriptional Regulation at Multiple Scales Using High-Throughput Sequencing, Data Integration, and Computational Methods Raymond Auerbach PhD Candidate, Yale University Gerstein and Snyder
More informationMRC-Holland MLPA. Description version 06; 23 December 2016
SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated
More informationDisclosure of Relevant Financial Relationships
Neuropathology Evening Specialty Conference Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME activities disclose
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationDifficult Diagnoses and Controversial Entities in Neoplastic Lung
Difficult Diagnoses and Controversial Entities in Neoplastic Lung Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Chief, Pulmonary Pathology Service Associate Professor, Harvard
More informationDisclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
More informationFinancial disclosures
Mesenchymal Neoplasms with Melanocytic Differentiation By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center Geisel
More informationCase Report SMARCB1 (INI1)-deficient sinonasal carcinoma: a newly described entity
Int J Clin Exp Pathol 2016;9(3):3454-3458 www.ijcep.com /ISSN:1936-2625/IJCEP0024095 Case Report SMARCB1 (INI1)-deficient sinonasal carcinoma: a newly described entity Ming Zeng 1*, Changrong Chen 2*,
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationNo financial or other disclosures
Case 2014-5 Esther N. Bit-Ivan, DO Northwestern University Jason Wang, MD Jason Park, MD Korgun Koral, MD Children s Medical Center Charles Timmons, MD Veena Rajaram, MD No financial or other disclosures
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More information3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project
Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship
More informationGene Expression DNA RNA. Protein. Metabolites, stress, environment
Gene Expression DNA RNA Protein Metabolites, stress, environment 1 EPIGENETICS The study of alterations in gene function that cannot be explained by changes in DNA sequence. Epigenetic gene regulatory
More informationPediatric Brain Tumor Research
Research into two rare and aggressive childhood brain tumors unveils discoveries that may be applicable well beyond those pediatric cancers. recent and ongoing research has led to important discoveries
More informationEZH2 Inhibitors as Novel Cancer Therapeutics!!!! Robert A. Copeland, Ph.D.! Epizyme, Inc.!!! 20 November 2014!
EZH2 Inhibitors as Novel Cancer Therapeutics Robert A. Copeland, Ph.D. Epizyme, Inc. 20 November 2014 2013 Accomplishments Disclosure Information EORTC-NCI-AACR Meeting, 20 November 2014 Robert A. Copeland,
More informationCase presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma
Genomic/morphological classification of endometrial carcinoma Robert A. Soslow, MD soslowr@mskcc.org architecture.about.com Case presentation 49 year old woman with vaginal bleeding Underwent endometrial
More informationCase 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset
Case 2 Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset History 24 year old male presented with a 3 day history of right flank pain, sharp in nature Denies fever, chills, hematuria or
More informationKlinisch belang van chromosomale translocatie detectie in sarcomen
Translocations in sarcomas Klinisch belang van chromosomale translocatie detectie in sarcomen Judith V.M.G. Bovée, M.D., Ph.D. Department of Pathology Leiden University Medical Center RNA binding DNA binding
More informationCutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
More informationKeywords solitary fibrous tumor, dedifferentiation, dedifferentiated solitary fibrous tumor, STAT6, GRIA2, cytokeratin, rhabdomyosarcomatous
758452IJSXXX10.1177/1066896918758452International Journal of Surgical PathologyCreytens et al research-article2018 Pitfalls in Pathology Multifocal Cytokeratin Expression in a Dedifferentiated Solitary
More informationRhabdoid tumor cells are characterized by large
Sarcomatoid renal cell carcinoma with rhabdoid features Nagla Ahmed Al-Saidi, Mohammed Akhtar From the King Faisal Specialist Hospital and Research Center - Pathology & Lab Medicine, Riyadh, Saudi Arabia
More informationCase Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr
Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationIMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
More informationMammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
HUMAN CANCER Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics 2015 he Authors, some rights reserved; exclusive licensee American Association
More informationThe SWI/SNF complex a potential target against ovarian cancer. Department of Medical Oncology, University Medical Center Groningen July 2014
The SWI/SNF complex a potential target against ovarian cancer Author: Luuk Heitink (S2186101) Supervisor: S. de Jong Department of Medical Oncology, University Medical Center Groningen Abstract The switch/sucrose
More informationFINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationIntroduction to Cancer Bioinformatics and cancer biology. Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015
Introduction to Cancer Bioinformatics and cancer biology Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015 Why cancer bioinformatics? Devastating disease, no cure on the horizon Major
More informationSelf assessment case. Dr Saleem Taibjee Dorset County Hospital, Dorchester
Self assessment case Dr Saleem Taibjee saleemtaibjee@gmail.com Dorset County Hospital, Dorchester Clinical details 34-year-old man: Shave excision Skin tag / papilloma left thigh The best diagnosis is:
More informationHaematology Probes for Multiple Myeloma
Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex
More informationDisclosure of Relevant Financial Relationships
Ewing and Ewing like sarcomas Using Genetic Signatures in Refining Small Blue Round Cell Tumor Classification Cristina Antonescu, MD Department of Pathology Disclosure of Relevant Financial Relationships
More informationPOORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?
POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT? AGGRESSIVE THYROID CANCERS PAPILLARY CARCINOMA CERTAIN SUBTYPES POORLY DIFFERENTIATED CARCINOMA HIGH GRADE DIFFERENTIATED
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationMolecular Gynaecological Pathology
Molecular Gynaecological Pathology Simon Herrington University of Edinburgh Division of Pathology Edinburgh Cancer Research Centre Institute of Genetics and Molecular Medicine Western General Hospital
More informationRenal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford
Renal tumours: use of immunohistochemistry & molecular pathology Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: the use of immunohistochemistry & molecular pathology Classification of RCC
More informationAlternative splicing. Biosciences 741: Genomics Fall, 2013 Week 6
Alternative splicing Biosciences 741: Genomics Fall, 2013 Week 6 Function(s) of RNA splicing Splicing of introns must be completed before nuclear RNAs can be exported to the cytoplasm. This led to early
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More informationAffiliazione autori0. Riccardo Ricci Journal Club GIPAD, settore GIST Anatomia Patologica, Università Cattolica, Roma
GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases American Journal of Surgical Pathology, 2017, 41:577-585 Miettinen M*; Felisiak-Golabek
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationTranscription and chromatin. General Transcription Factors + Promoter-specific factors + Co-activators
Transcription and chromatin General Transcription Factors + Promoter-specific factors + Co-activators Cofactor or Coactivator 1. work with DNA specific transcription factors to make them more effective
More informationLiposarcoma*Genome*Project*
LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue
More informationCase: The patient is a 24 year- old female who was found to have multiple mural nodules within the antrum. Solid and cystic components were noted on
Case: The patient is a 24 year- old female who was found to have multiple mural nodules within the antrum. Solid and cystic components were noted on imaging. There is no significant past medical history.
More informationMammary analogue secretory carcinoma of salivary gland A case report of new entity
Case Report Mammary analogue secretory carcinoma of salivary gland A case report of new entity Vaibhav Bhika Bari 1*, Sandhya Unmesh Bholay 2 1 Assistant Professor, 2 Associate Professor Rajiv Gandhi Medical
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More informationACCME/Disclosures ALK FUSION-POSITIVE MESENCHYMAL TUMORS. Tumor types with ALK rearrangements. Anaplastic Lymphoma Kinase. Jason L.
Companion Meeting of the International Society of Bone and Soft Tissue Pathology The Evolving Concept of Mesenchymal Tumors ALK FUSION-POSITIVE MESENCHYMAL TUMORS Jason L. Hornick, MD, PhD March 13, 2016
More informationCase 1. Clinical history
Case 1 Case 1 Clinical history 17-month-old boy with a kidney tumor found during routine childhood care program. CT scan showed a solid mass. Chemotherapy was given for 4 weeks using actinomycin D and
More informationRhabdoid variant of UC
Int J Clin Exp Pathol 2015;8(8):9638-9642 www.ijcep.com /ISSN:1936-2625/IJCEP0011287 Case Report Rhabdoid variant of urothelial carcinoma of the urinary bladder: a case report with emphasis on immunohistochemical
More informationFinancial disclosures
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchc Geisel School of
More informationWhat All of Us Should Know About Cancer and Genetics
What All of Us Should Know About Cancer and Genetics Beth A. Pletcher, MD, FAAP, FACMG Associate Professor of Pediatrics UMDNJ- New Jersey Medical School Disclosures I have no relevant financial relationships
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationUSCAP 2012: Companion Meeting of the AAOOP. Update on lacrimal gland neoplasms: Molecular pathology of interest
USCAP 2012: Companion Meeting of the AAOOP Vancouver BC, Canada, March 17, 2012 Update on lacrimal gland neoplasms: Molecular pathology of interest Valerie A. White MD, MHSc, FRCPC Department of Pathology
More information609G: Concepts of Cancer Genetics and Treatments (3 credits)
Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,
More informationThe Genetics of Myoepithelial Tumors: salivary glands, soft tissue and bone
The Genetics of Myoepithelial Tumors: salivary glands, soft tissue and bone Cristina Antonescu, MD Memorial Sloan-Kettering Cancer Center, New York Nothing to declare Disclosure Spectrum of Myoepithelial
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More information21/07/2017. Hobnail endothelial cells are not the same as epithelioid endothelial cells
UPDATE IN CUTANEOUS VASCULAR S DERMATOPATHOLOGY SESSION BELFAST PATHOLOGY JUNE 21/2017 Dr E Calonje St John s Institute of Dermatology, London, United Kingdom THE FAMILY OF VASCULAR S WITH EPITHELIOID
More informationCase 1. Disclosure. Imaging. Clinical history 5/10/2016. USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology
Disclosure Dr. Agaram has nothing to disclose Case 1 Narsi Agaram, MBBS USCAP 2016 Annual Meeting Evening Specialty Conference Bone and Soft tissue Pathology Clinical history Imaging 1998 A three month
More informationChromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011
Chromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011 Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development Cell 144,
More informationESS: Pathologic Insights
GEIS XVI INTERNATIONAL SYMPOSIUM Seville 4th October 2018 ESS: Pathologic Insights Sílvia Bagué The Royal Marsden Hospital London (United Kingdom) I have no conflicts of interest Endometrial stromal sarcoma
More informationMolecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls
Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls Cristina Antonescu, MD Department of Pathology Memorial Sloan-Kettering Cancer Center, New York Overview I. When should we rely on the help of
More informationImmunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
More informationSoluble N-cadherin as a Biomarker for Malignant Bone and Soft Tissue Tumors
Soluble N-cadherin as a Biomarker for Malignant Bone and Soft Tissue Tumors Akihiko Matsumine, Rui Niimi, Takahiro Iino, Tomoki Nakamura, Takao Matsubara, Kunihiro Asanuma, Akihiro Sudo, Prof.. Mie University
More informationClonal evolution of human cancers
Clonal evolution of human cancers -Pathology-based microdissection and genetic analysis precisely demonstrates molecular evolution of neoplastic clones- Hiroaki Fujii, MD Ageo Medical Laboratories, Yashio
More informationMyxo-inflammatory Fibroblastic sarcoma
AKA Myxo-inflammatory Fibroblastic sarcoma Acral Myxoinflammatory fibroblastic sarcomaam.j.surg.path1998; 22; 911-924 Inflammatory myxoid tumour of soft parts with bizarre giant cells [Pathol.Res.Pract.
More informationInvited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology
Histol Histopathol (1 999) 14: 269-277 http://www.ehu.es/histol-histopathol Histology and Histo pathology Invited Re vie W Molecular genetics of ovarian carcinomas J. Diebold Pathological Institute, Ludwig-Maximilians-University
More informationEvaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment
The Open Pathology Journal, 2009, 3, 53-57 53 Open Access Evaluating and Reporting Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment Katie L. Dennis * and Ivan Damjanov Department of Pathology
More informationRARE TUMORS OF INFANCY. RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital
RARE TUMORS OF INFANCY RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital OBJECTIVES Review the epidemiology and clinical presentation of soft tissue sarcomas in infancy.
More informationCurrent Concept in Ovarian Carcinoma: Pathology Perspectives
Current Concept in Ovarian Carcinoma: Pathology Perspectives Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine Current Concept in Ovarian
More informationEvening Specialty Conference Bone and Soft Tissue Pathology. Diagnostic pitfalls in bone and soft tissue pathology
Evening Specialty Conference Bone and Soft Tissue Pathology. Case 1 Elizabeth G Demicco, MD, PhD Mount Sinai Hospital, New York Disclosure of Relevant Financial Relationships USCAP requires that all planners
More informationof 20 to 80 and subsequently declines [2].
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
More informationAANP Diagnostic Slide Session Case 5
AANP Diagnostic Slide Session Case 5 E. Kelly S. Mrachek, M.D. Neuropathology Fellow University of Virginia M. Beatriz S. Lopes, M.D., Ph.D. Neuropathology Program Director University of Virginia Disclosures:
More informationGenetic Predisposition to Cancer
Genetic Predisposition to Cancer Elena Castro, MD, PhD Prostate Cancer and GU tumours Unit Spanish National Cancer Research Centre Madrid, Spain Abstract 750O: Early detection of hereditary renal cell
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationImprinting. Joyce Ohm Cancer Genetics and Genomics CGP-L2-319 x8821
Imprinting Joyce Ohm Cancer Genetics and Genomics CGP-L2-319 x8821 Learning Objectives 1. To understand the basic concepts of genomic imprinting Genomic imprinting is an epigenetic phenomenon that causes
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More information59 yo male with past medical history of prostate carcinoma, presented with upper abdominal pain
December 2016 59 yo male with past medical history of prostate carcinoma, presented with upper abdominal pain Contributed by: Divya Sharma, MD. Fellow, Gastrointestinal Pathology, Department of Pathology
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationThe Relevance of Cytologic Atypia in Cutaneous Neural Tumors
The Relevance of Cytologic Atypia in Cutaneous Neural Tumors Recent Findings - New Developments New Problems Zsolt B. Argenyi, M.D. Professor of Pathology & Dermatology Director of Dermatopathology Department
More informationSurgical Pathology Evening Specialty Conference USCAP 2015
Surgical Pathology Evening Specialty Conference USCAP 2015 John R. Goldblum, M.D. Chairman, Department of Pathology, Cleveland Clinic Professor of Pathology, Cleveland Clinic Lerner College of Medicine
More informationLecture 10. Eukaryotic gene regulation: chromatin remodelling
Lecture 10 Eukaryotic gene regulation: chromatin remodelling Recap.. Eukaryotic RNA polymerases Core promoter elements General transcription factors Enhancers and upstream activation sequences Transcriptional
More information3/27/2017. Disclosure of Relevant Financial Relationships
Ophthalmic Pathology Evening Specialty Conference USCAP 2017 5 th March, 2017 Mukul K. Divatia, MD Assistant Professor Department of Pathology & Genomic Medicine Weill Cornell Medical College Houston Methodist
More informationSoft Tissue High Grade Myoepithelial Carcinoma With Round Cell Morphology: Report Of A Newly Described Entity With EWSR1 Gene Rearrangement
Soft Tissue High Grade Myoepithelial Carcinoma With Round Cell Morphology: Report Of A Newly Described Entity With EWSR1 Gene Rearrangement Abstract M. El-Kabany, R. Al-Abdulghani, A. E. Ali, I. M. Francis,
More informationComputational Systems Biology: Biology X
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH
More informationAdenocarcinoma of the pancreas
Adenocarcinoma of the pancreas SEMINARS IN DIAGNOSTIC PATHOLOGY 31 (2014) 443 451 Ralph H.Hruban, MD, David S. Klimstra, MD Paola Parente Anatomia Patologica Casa Sollievo della Sofferenza San Giovanni
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationTumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationSystems Analysis Of Chromatin-Related Protein Complexes In Cancer READ ONLINE
Systems Analysis Of Chromatin-Related Protein Complexes In Cancer READ ONLINE If looking for the book Systems Analysis of Chromatin-Related Protein Complexes in Cancer in pdf format, then you have come
More information